The company has received approval to list 4,51,66,668 new equity shares. These shares were previously issued on a preferential basis to both promoter and non-promoter investors. This approval allows these new shares to be officially traded on the exchange, completing the capital infusion process and potentially increasing the total number of shares available in the market.